Landmark trials in endocrine adjuvant therapy for breast carcinoma

William Gradishar1

  • 1Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA. w-gradishar@northwestern.edu

Cancer
|January 26, 2006
PubMed

Insights

Aromatase inhibitors are crucial in breast cancer treatment, guiding current American Society of Clinical Oncology recommendations. Landmark trials shaped these therapeutic strategies for breast carcinoma.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Breast carcinoma treatment has evolved significantly.
  • Hormonal therapies play a key role in managing certain breast cancers.

Purpose of the Study:

  • To review landmark clinical trials on aromatase inhibitors.
  • To outline their impact on current breast cancer treatment guidelines.

Main Methods:

  • Literature review of pivotal studies.
  • Analysis of trial outcomes and meta-analyses.

Main Results:

  • Aromatase inhibitors demonstrated significant efficacy in multiple trials.
  • Established aromatase inhibitors as a cornerstone therapy for hormone receptor-positive breast cancer.

Conclusions:

  • Landmark trials have solidified the role of aromatase inhibitors in breast carcinoma management.
  • Current therapeutic approaches for breast cancer are informed by these critical research findings.